Engineered immune cells take on Hard-to-Treat lymphoma
Disease control
Recruiting now
This early-stage trial tests a new treatment called Senza5 CART5 for people with a type of T cell lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to better target and attack cancer cells. The main goal …
Phase: PHASE1 • Sponsor: Vittoria Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC